Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance
出版年份 2022 全文链接
标题
Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance
作者
关键词
-
出版物
Cell Reports
Volume 40, Issue 6, Pages 111177
出版商
Elsevier BV
发表日期
2022-08-09
DOI
10.1016/j.celrep.2022.111177
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute
- (2022) Kelvin César de Andrade et al. CELL DEATH AND DIFFERENTIATION
- BRD4-mediated repression of p53 is a target for combination therapy in AML
- (2021) Anne-Louise Latif et al. Nature Communications
- Chemical Phosphoproteomics Sheds New Light on the Targets and Modes of Action of AKT Inhibitors
- (2021) Svenja Wiechmann et al. ACS Chemical Biology
- Integrated intra‐ and intercellular signaling knowledge for multicellular omics analysis
- (2021) Dénes Türei et al. Molecular Systems Biology
- Spatial-proteomics reveals phospho-signaling dynamics at subcellular resolution
- (2021) Ana Martinez-Val et al. Nature Communications
- SciPy 1.0: fundamental algorithms for scientific computing in Python
- (2020) Pauli Virtanen et al. NATURE METHODS
- Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome
- (2020) D.G.J. Cucchi et al. DRUG RESISTANCE UPDATES
- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- Protein aggregation capture on microparticles enables multi-purpose proteomics sample preparation.
- (2019) Tanveer Singh Batth et al. MOLECULAR & CELLULAR PROTEOMICS
- Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia
- (2019) Bruno C. Medeiros et al. AMERICAN JOURNAL OF HEMATOLOGY
- Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
- (2019) Bhavana Bhatnagar et al. LEUKEMIA & LYMPHOMA
- Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc
- (2019) Yuki Nishida et al. BLOOD
- Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
- (2019) Kendra Sweet et al. CLINICAL CANCER RESEARCH
- The functional landscape of the human phosphoproteome
- (2019) David Ochoa et al. NATURE BIOTECHNOLOGY
- Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML
- (2018) Lauren Herschbein et al. BLOOD REVIEWS
- A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
- (2018) Amy Y. Wang et al. Journal of Hematology & Oncology
- Benchmarking common quantification strategies for large-scale phosphoproteomics
- (2018) Alexander Hogrebe et al. Nature Communications
- Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
- (2018) Vinod Vijay Subhash et al. Scientific Reports
- Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis
- (2018) Ina Nepstad et al. Cancers
- Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma
- (2018) Kristina B. Emdal et al. Science Signaling
- Optimization of Experimental Parameters in Data-Independent Mass Spectrometry Significantly Increases Depth and Reproducibility of Results
- (2017) Roland Bruderer et al. MOLECULAR & CELLULAR PROTEOMICS
- The target landscape of clinical kinase drugs
- (2017) Susan Klaeger et al. SCIENCE
- Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer
- (2017) Chiara Francavilla et al. Cell Reports
- DAPAR & ProStaR: software to perform statistical analyses in quantitative discovery proteomics
- (2016) Samuel Wieczorek et al. BIOINFORMATICS
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma
- (2016) Rebecca S. Lescarbeau et al. MOLECULAR CANCER THERAPEUTICS
- The Perseus computational platform for comprehensive analysis of (prote)omics data
- (2016) Stefka Tyanova et al. NATURE METHODS
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants
- (2016) Ke Chen et al. Oncotarget
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
- (2014) M. Y. Konopleva et al. CLINICAL CANCER RESEARCH
- PhosphoSitePlus, 2014: mutations, PTMs and recalibrations
- (2014) Peter V. Hornbeck et al. NUCLEIC ACIDS RESEARCH
- Atomic basis of CRM1-cargo recognition, release and inhibition
- (2014) Ho Yee Joyce Fung et al. SEMINARS IN CANCER BIOLOGY
- Prognostic impact and targeting of CRM1 in acute myeloid leukemia
- (2013) K. Kojima et al. BLOOD
- KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia
- (2013) Julia Etchin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods
- (2013) Leif Väremo et al. NUCLEIC ACIDS RESEARCH
- Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells
- (2013) P. Casado et al. Science Signaling
- CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo
- (2013) Joel G. Turner et al. Journal of Cancer
- Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
- (2012) P. Ranganathan et al. BLOOD
- An overview of the mTOR pathway as a target in cancer therapy
- (2012) Ryan D Gentzler et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Identification of CRM1-dependent Nuclear Export Cargos Using Quantitative Mass Spectrometry
- (2012) Ketan Thakar et al. MOLECULAR & CELLULAR PROTEOMICS
- InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation
- (2012) Karin Breuer et al. NUCLEIC ACIDS RESEARCH
- mTORC1 Directly Phosphorylates and Regulates Human MAF1
- (2010) A. A. Michels et al. MOLECULAR AND CELLULAR BIOLOGY
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors
- (2010) J. N. Andersen et al. Science Translational Medicine
- The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is dependent on its association with the protein tyrosine phosphatase SHP-1
- (2009) C.F. Sephton et al. CELLULAR SIGNALLING
- Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML
- (2009) Alexandra Boehm et al. European Journal of Internal Medicine
- Improved visualization of protein consensus sequences by iceLogo
- (2009) Niklaas Colaert et al. NATURE METHODS
- Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome
- (2008) Fernando Callera et al. LEUKEMIA RESEARCH
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
- (2008) Jürgen Cox et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now